Literature DB >> 23932362

Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

Vincenzo Pitini1, Carmela Arrigo, Cristian Di Mirto, Patrizia Mondello, Giuseppe Altavilla.   

Abstract

We report a patient with squamous cell carcinoma (SQCC) of the lung and a discoid-receptor-2 (DDR2) kinase domain mutation that responded to dasatinib treatment. Our case report is consistent with previous publications suggesting that DDR2 mutation may confer sensitivity to dasatinib.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chronic myelogenous leukemia; DDR2; Dasatinib; Driver mutations; Squamous-cell carcinoma; Targeted therapies

Mesh：

Substances：

Year:  2013        PMID： 23932362     DOI： 10.1016/j.lungcan.2013.07.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  24 in total

1.  Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis.

Authors:  Hu Zhao; Huan Bian; Xin Bu; Shuya Zhang; Pan Zhang; Jiangtian Yu; Xiaofeng Lai; Di Li; Chuchao Zhu; Libo Yao; Jin Su
Journal:  Mol Ther       Date:  2016-05-27       Impact factor: 11.454

2.  Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

Authors:  Eric B Haura; Uwe Rix
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

3.  Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

Authors:  Yun Bai; Jae-Young Kim; January M Watters; Bin Fang; Fumi Kinose; Lanxi Song; John M Koomen; Jamie K Teer; Kate Fisher; Yian Ann Chen; Uwe Rix; Eric B Haura
Journal:  Cancer Res       Date:  2014-10-27       Impact factor: 12.701

4.  Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristina Y Aguilera; Huocong Huang; Wenting Du; Moriah M Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B Fleming; Diego H Castrillon; Xiaomei Ren; Ke Ding; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

5.  Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Authors:  Matthew L Hedberg; Gerald Goh; Simion I Chiosea; Julie E Bauman; Maria L Freilino; Yan Zeng; Lin Wang; Brenda B Diergaarde; William E Gooding; Vivian W Y Lui; Roy S Herbst; Richard P Lifton; Jennifer R Grandis
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

6.  Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.

Authors:  Ellen M Beauchamp; Brittany A Woods; Austin M Dulak; Li Tan; Chunxiao Xu; Nathanael S Gray; Adam J Bass; Kwok-kin Wong; Matthew Meyerson; Peter S Hammerman
Journal:  Mol Cancer Ther       Date:  2013-12-02       Impact factor: 6.261

7.  Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).

Authors:  Andrew B Lassman; Stephanie L Pugh; Mark R Gilbert; Kenneth D Aldape; Sandrine Geinoz; Jan H Beumer; Susan M Christner; Ritsuko Komaki; Lisa M DeAngelis; Rakesh Gaur; Emad Youssef; Henry Wagner; Minhee Won; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2015-03-10       Impact factor: 12.300

Review 8.  Prognostic and predictive biomarkers in lung cancer. A review.

Authors:  Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal:  Virchows Arch       Date:  2014-01-14       Impact factor: 4.064

9.  Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.

Authors:  Marcin Nicoś; Tomasz Powrózek; Paweł Krawczyk; Bożena Jarosz; Beata Pająk; Marek Sawicki; Krzysztof Kucharczyk; Tomasz Trojanowski; Janusz Milanowski
Journal:  Med Oncol       Date:  2014-08-31       Impact factor: 3.064

Review 10.  Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Authors:  Catherine B Meador; Christine M Micheel; Mia A Levy; Christine M Lovly; Leora Horn; Jeremy L Warner; Douglas B Johnson; Zhongming Zhao; Ingrid A Anderson; Jeffrey A Sosman; Cindy L Vnencak-Jones; Kimberly B Dahlman; William Pao
Journal:  Clin Cancer Res       Date:  2014-03-05       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.